Natural Products Insider

NOV-DEC 2018

INSIDER is the leading information source for marketers, manufacturers and formulators of dietary supplements, healthy foods and cosmeceuticals. Since 1997, INSIDER has been serving the needs of the global nutrition industry.

Issue link: http://digital.naturalproductsinsider.com/i/1036004

Contents of this Issue

Navigation

Page 41 of 166

naturalproductsinsider.com/ashwagandha-advantage 7 Ashwagandha for Hypothyroidism THEORY: Subclinical hypothyroidism (SCH)—or mild thyroid ĨĂŝůƵƌĞŝƐĞƐƟŵĂƚĞĚƚŽ occur in up to 8 percent of the total ƉŽƉƵůĂƟŽŶǁŝƚŚĂŚŝŐŚĞƌŝŶĐŝĚĞŶĐĞĂŵŽŶŐ ǁŽŵĞŶƉĂƌƟĐƵůĂƌůLJƚŚŽƐĞƐƵīĞƌŝŶŐĨƌŽŵ ,ĂƐŚŝŵŽƚŽƐƚŚLJƌŽŝĚŝƟƐĂĐŚƌŽŶŝĐĂƵƚŽŝŵŵƵŶĞ ĚŝƐŽƌĚĞƌdŚĞŽŶůLJĂƉƉƌŽǀĞĚƚƌĂĚŝƟŽŶĂůƚŚĞƌĂƉLJ is not reliable and carries health risks. Instead, ĐŽƵůĚƚŚĞƵƐĞŽĨĂƐŚǁĂŐĂŶĚŚĂƚƌĂĚŝƟŽŶĂůůLJ used for hormonal disorders in Ayurveda, act as an adaptogen to address SCH? PARAMETERS: A single-center,ƉƌŽƐƉĞĐƟǀĞĚŽƵďůĞďůŝŶĚƌĂŶĚŽŵŝnjĞĚ placebo-controlled, parallel group trial was conducted at ^ƵĚďŚĂǁĂŶĂ,ŽƐƉŝƚĂůsĂƌĂŶĂƐŝ/ŶĚŝĂ^ƵďũĞĐƚƐ;ŶсϱϬŚĂĚ ƐĞƌƵŵƚŚLJƌŽŝĚƐƟŵƵůĂƟŶŐŚŽƌŵŽŶĞ;d^,ůĞǀĞůƐďĞƚǁĞĞŶϰϱĂŶĚ ϭϬђ/h•>ĂŶĚŶŽƌŵĂůƐĞƌƵŵdϯĂŶĚdϰůĞǀĞůƐKǀĞƌĞŝŐŚƚǁĞĞŬƐ ƐƵďũĞĐƚƐƌĞĐĞŝǀĞĚϯϬϬŵŐŽĨĂƐŚǁĂŐĂŶĚŚĂ;ĂƐ<^DϲϲƚǁŝĐĞĚĂŝůLJ ŽƌƉůĂĐĞďŽĨŽƌĞŝŐŚƚǁĞĞŬƐĸĐĂĐLJǁĂƐĂƐƐĞƐƐĞĚďLJĞǀĂůƵĂƟŶŐ serum TSH, T3 and T4 levels at baseline, four weeks and eight weeks; physical, vital and hematologic parameters were monitored to ĚĞƚĞƌŵŝŶĞƐĂĨĞƚLJŽĨƚŚĞŝŶƚĞƌǀĞŶƟŽŶ&ŽƵƌƐƵďũĞĐƚƐ;ƚǁŽĨƌŽŵ each group) withdrew consent before the four-week visit. ^ŽƵƌĐĞ^ŚĂƌŵĂ<ĂƐƵ/^ŝŶŐŚ^ĸĐĂĐLJĂŶĚ^ĂĨĞƚLJŽĨƐŚǁĂŐĂŶĚŚĂZŽŽƚdžƚƌĂĐƚŝŶ^ƵďĐůŝŶŝĐĂů,LJƉŽƚŚLJƌŽŝĚWĂƟĞŶƚƐŽƵďůĞůŝŶĚZĂŶĚŽŵŝnjĞĚWůĂĐĞŶƚƌŽůůĞĚdƌŝĂů• :ůƚĞƌŶĂƟǀĞŽŵƉůĞŵĞŶƚĂƌLJDĞĚϮϬϭϳK/ϭϬϭϬ• -ĂĐŵϮϬϭϳϬϭ•ϯ IMPACT: Subclinical hypothyroidismŵĂLJĂīĞĐƚƵƉƚŽϭ•ƉĞƌĐĞŶƚŽĨĞůĚĞƌůLJĂĚƵůƚƐĂŶĚĐĂŶŝŶĐƌĞĂƐĞƚŚĞrisk of coronary heart disease and heart failure, 1 ĂŶĚŵĂLJĂĚǀĞƌƐĞůLJĂīĞĐƚďŽŶĞŵŝŶĞƌĂůĚĞŶƐŝƚLJĂŶĚŝŶĐƌĞĂƐĞƚŚĞ risk of fracture. 2 However, the most common treatment—levothyroxine—is controversial and may provide ŶŽďĞŶĞĮƚ 3 /ŶƐƚĞĂĚƌĞƐĞĂƌĐŚĞƌƐĂŶĚƉƌĂĐƟƟŽŶĞƌƐĂƌĞůŽŽŬŝŶŐĨŽƌĂůƚĞƌŶĂƟǀĞǁĂLJƐƚŽŶĂƚƵƌĂůůLJƐƵƉƉŽƌƚ ƚŚLJƌŽŝĚĨƵŶĐƟŽŶtŝƚŚŝƚƐŚŝƐƚŽƌŝĐĂůƵƐĞĂƐĂŶĂĚĂƉƚŽŐĞŶǁŝƚŚƉŽƐŝƟǀĞďĂůĂŶĐŝŶŐĞīĞĐƚƐŽŶƚŚĞďŽĚLJ ashwagandha (Withania somnifera ƵŶĂůŵĂLJŚĂǀĞĂƌŽůĞƚŽƉůĂLJŝŶƐƵƉƉŽƌƟŶŐŚĞĂůƚŚLJƚŚLJƌŽŝĚĨƵŶĐƟŽŶ 1. Swiss Med Wkly. 2014 Dec 23;144:w14058 2. J Endocrinol Invest. 2017 Aug 29. DOI: 10.1007/s40618-017-0753-4 ϯ NEJM. 2017;376:2534-2544 ŬƐŵϲϲĂƐŚǁĂŐĂŶĚŚĂĂĐŽŵ ^ŽƵƌĐĞ/ŶĨŽŐƌĂƉŚŝĐďƌŽƵŐŚƚƚŽLJŽƵďLJ OUTCOME: Ō ĞƌĞŝŐŚƚǁĞĞŬƐĂĚƵůƚƐƚĂŬŝŶŐĂƐŚǁĂŐĂŶĚŚĂŚĂĚ Researchers concluded: ZĞƐĞĂƌĐŚĞƌƐĐŝƚĞĚůŝŵŝƚĂƟŽŶƐǁŝƚŚƚŚĞƐŵĂůůƐĂŵƉůĞƐŝnjĞĂŶĚƐƚƵĚLJĚƵƌĂƟŽŶ ƌĞĐŽŵŵĞŶĚŝŶŐĨƵƌƚŚĞƌŝŶǀĞƐƟŐĂƟŽŶǁŝƚŚĂůĂƌŐĞƌƉŽƉƵůĂƟŽŶĂŶĚůŽŶŐĞƌĚƵƌĂƟŽŶ,ŽǁĞǀĞƌƚŚĞLJ ĐŽŶĐůƵĚĞĚ€‚dƌĞĂƚŵĞŶƚǁŝƚŚĂƐŚǁĂŐĂŶĚŚĂŵĂLJďĞďĞŶĞĮĐŝĂůĨŽƌŶŽƌŵĂůŝnjŝŶŐƚŚLJƌŽŝĚŝŶĚŝĐĞƐŝŶ ƐƵďĐůŝŶŝĐĂůŚLJƉŽƚŚLJƌŽŝĚƉĂƟĞŶƚƐƒ ^ŝŐŶŝĮĐĂŶƚůLJĚĞĐƌĞĂƐĞĚƐĞƌƵŵ d^,ůĞǀĞůƐcompared to placebo at four and eight weeks. ĐŚĂŶŐĞƐĨƌŽŵďĂƐĞůŝŶĞǁĞƌĞƐƚĂƟƐƟĐĂůůLJƐŝŐŶŝĮĐĂŶƚĐŽŵƉĂƌĞĚ to the placebo group. Increases in dϯůĞǀĞůƐ by at four weeks and 41.5 % 18.6 % by eight weeks; ǁŚŝĐŚǁĞƌĞƐŝŐŶŝĮĐĂŶƚĐŽŵƉĂƌĞĚƚŽƉůĂĐĞďŽ /ŶĐƌĞĂƐĞĚdϰůĞǀĞůƐ from baseline by at four weeks and 19.6 % 9.3 % three in placebo Four subjects— ƌĞƉŽƌƚĞĚŵŝůĚƚĞŵƉŽƌĂƌLJĂĚǀĞƌƐĞĞīĞĐƚƐ and one taking ashwagandha—

Articles in this issue

Links on this page

Archives of this issue

view archives of Natural Products Insider - NOV-DEC 2018